Abstract
1. Cumulative administrations of U46619, a thromboxane A2 analogue, and prostaglandin (PG) F2 alpha produced concentration-dependent contractions of isolated dog renal arterial preparations, which were significantly and concentration-dependently inhibited by vapiprost. 2. A bolus administration of U46619 or PGF2 alpha produced sustained contracture of these preparations, which was concentration-dependently relaxed by cumulative vapiprost. 3. Results indicate that vapiprost inhibits U46619- and PGF2 alpha-induced dog renal arterial contractions through antagonism for so-called TP receptors.
MeSH terms
-
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
-
Animals
-
Biphenyl Compounds / pharmacology*
-
Dinoprost / pharmacology
-
Dogs
-
Dose-Response Relationship, Drug
-
Female
-
Heptanoic Acids / pharmacology*
-
In Vitro Techniques
-
Male
-
Prostaglandin Endoperoxides, Synthetic / pharmacology*
-
Receptors, Thromboxane / antagonists & inhibitors*
-
Renal Artery / drug effects*
-
Renal Artery / physiology
-
Thromboxane A2 / analogs & derivatives*
-
Thromboxane A2 / pharmacology
-
Vasoconstriction / drug effects*
-
Vasoconstrictor Agents / pharmacology*
Substances
-
Biphenyl Compounds
-
Heptanoic Acids
-
Prostaglandin Endoperoxides, Synthetic
-
Receptors, Thromboxane
-
Vasoconstrictor Agents
-
Thromboxane A2
-
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
-
Dinoprost
-
vapiprost